Cubosomes as Oral Drug Delivery Systems: A Promising Approach for Enhancing the Release of Clopidogrel Bisulphate in the Intestine

Chemical & Pharmaceutical Bulletin
Hanan M El-LaithyNihal El-Sayyad

Abstract

Clopidogrel bisulphate (CB) is a first line antiplatelet drug for treatment of myocardial infarction and stroke. Yet, its efficacy is limited by its poor solubility in intestinal pH, its main site of absorption. The main aim of this study is to enhance the intestinal release of CB by loading in cubosome nanoparticles. Glyceryl monooleate (GMO) based CB loaded cubosomes were prepared using a 33 factorial design to study the effect of polyvinyl alcohol (PVA), poloxamer 407 (PL407) concentrations and ratio of CB to the disperse phase on the average particle size, entrapment efficiency (%EE), in vitro release at 15 min (%Q15), and their morphology using transmission electron microscopy (TEM). The release of the optimized formula was compared in buffer transition media (pH 1.2 for 2 h then pH 6.8 for 6 h) to free drug to study the effect of the changing pH in the gastrointestinal tract (GIT) on CB release. The antihaemostatic properties of the optimized formula were compared to the commercial product Plavix® using bleeding time (BT) model in rabbits. The prepared cubosomes were in the nano range (115±6.47 to 248±4.63 nm) with high %EE (91.22±4.09% to 98.98±3.21%). The optimized formula showed significantly higher (p<0.05) CB release...Continue Reading

References

Jul 20, 2000·Drug Development and Industrial Pharmacy·A Ganem-QuintanarP Buri
Apr 20, 2001·Advanced Drug Delivery Reviews·J C ShahD M Chilukuri
Jul 5, 2003·International Journal of Pharmaceutics·Ben J Boyd
Jun 17, 2004·AAPS PharmSci·Elisabetta EspositoRita Cortesi
Aug 31, 2004·The Journal of Chemical Physics·A S Barnard, P Zapol
Jul 2, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·J Clogston, M Caffrey
Jul 26, 2005·British Journal of Pharmacology·Laura MoleroCarlos Macaya
Nov 4, 2005·Pharmaceutical Research·Elisabetta EspositoCarmelo Puglia
Dec 11, 2007·Advanced Drug Delivery Reviews·Colin W Pouton, Christopher J H Porter
May 5, 2010·Pharmacogenetics and Genomics·Katrin SangkuhlRuss B Altman
Nov 11, 2010·Pharmaceutical Development and Technology·Celil Tan, İsmail Tuncer Degim
Mar 17, 2012·The Journal of Pharmacy and Pharmacology·Mohamed Ali LassouedFathia Khemiss
May 22, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Nadia M MorsiMohammed A Ahmed
Oct 16, 2013·Clinical Pharmacokinetics·Marta Karaźniewicz-ŁadaFranciszek Główka
Jun 21, 2014·Journal of Neurogastroenterology and Motility·Pataramon VasavidSutep Gonlachanvit
Mar 10, 2015·Expert Opinion on Drug Delivery·Terence E HartnettKatharina Ladewig
Nov 19, 2015·Acta Pharmaceutica Sinica. B·Mohamed NasrAhmed Abdelazem
Dec 2, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Dina E BaliGamal M El Maghraby
Jan 5, 2017·Chemical & Pharmaceutical Bulletin·Md Ashraf AliShigeru Itai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.